Summary

Middle East Biomarker-Based Immunoassays Market Summary

The Middle East biomarker-based immunoassays market size was estimated at USD 114.23 million in 2024 and is projected to reach USD 159.25 million by 2033, growing at a CAGR of 3.61% from 2025 to 2033. The market growth is driven by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has led clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring.

Countries such as Saudi Arabia, the UAE, and Kuwait are growing and investing heavily in diagnostic infrastructure and adopting international best practices. A growing trend in the market is the push for deeper partnerships between global diagnostic firms and local healthcare providers. A recent example came in January 2025, when Diatech Pharmacogenetics broadened its work with Merck to give colorectal cancer patients in the Middle East better access to RAS biomarker testing. Moves like this show how strongly the region is leaning toward personalized cancer care. These alliances do not just improve the reach of biomarker assays-they also bring new technologies into local systems and build expertise on the ground. For many international companies, the Middle East is starting to look like one of the most promising areas for growth in precision diagnostics.

The Middle East region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments in countries like Saudi Arabia and the UAE have been putting serious money into diagnostic capacity so they do not have to rely as much on overseas labs. That shift is opening the door for local manufacturing and technology transfer. At the same time, lifestyle-driven diseases are becoming more common, which makes early detection and personalized treatment more important in areas such as oncology, cardiology, and neurology. With more attention now on value-based care, biomarker testing is seen as a practical way to lower costs while still improving patient outcomes.

Strategic collaborations are playing an important role in driving the Middle East biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in the Middle East’s expanding clinical research networks. In the meantime, regional organizations are demonstrating their dedication to becoming a center for precision diagnostics innovation by introducing cutting-edge biomarker testing programs that work with international standards, such as King Faisal Specialist Hospital in Saudi Arabia.

Middle East Biomarker-Based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East biomarker-based immunoassays market report based on sample, product, biomarkers, diseases, end use, and region:

• Sample Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Tissue
• Urine
• Saliva
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments/Analyzers
• Reagent & Kits
• Services
• Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
• Safety & toxicity biomarkers
• Efficacy & Pharmacodynamic Biomarkers
• Predictive & Prognostic Biomarkers
• Surrogate/Exploratory Biomarkers
• Diseases Outlook (Revenue, USD Million, 2021 - 2033)
• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East
o Saudi Arabia
o UAE
o Kuwait
o Oman
o Qatar
o Rest of Middle East

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Sample Segment
1.2.2. Product Segment
1.2.3. Biomarker Segment
1.2.4. Diseases Segment
1.2.5. End Use Segment
1.3. Information analysis
1.3.1. Market formula,tion & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Biomarker
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Middle East Biomarker-Based Immunoassays Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for precision medicine and personalized therapies
3.2.1.2. Increasing prevalence of chronic and infectious diseases
3.2.1.3. Technological advancements in immunoassay platforms
3.2.2. Market restraint analysis
3.2.2.1. High cost of advanced biomarker assays and platforms
3.3. Middle East Biomarker-Based Immunoassays Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Middle East Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Biomarker-Based Immunoassays Market Sample Movement Analysis
4.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2033 (USD Million)
4.4. Blood
4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Tissue
4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Saliva
4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Urine
4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Middle East Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Biomarker-Based Immunoassays Market Product Movement Analysis
5.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
5.4. Consumables
5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Instruments/Analyzers
5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Reagent & Kits
5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Services
5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Middle East Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Biomarker-Based Immunoassays Market Biomarker Movement Analysis
6.3. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
6.4. Safety & toxicity biomarkers
6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Efficacy & Pharmacodynamic Biomarkers
6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Predictive & Prognostic Biomarkers
6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Surrogate/Exploratory Biomarkers
6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Middle East Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East Biomarker-Based Immunoassays Market Diseases Movement Analysis
7.2.1. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
7.3. Cancer
7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
7.4. Cardiovascular Diseases
7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Neurological Diseases
7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Immunological Diseases
7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Others
7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Middle East Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Middle East Biomarker-Based Immunoassays Market End Use Movement Analysis
8.2.1. Middle East Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.3. Hospitals & Clinics
8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
8.4. Diagnostic Laboratories
8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Research & Academic Institutes
8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Others
8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Middle East Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis
9.1. Regional Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.3. Middle East
9.3.1. Oman
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework/ reimbursement structure
9.3.1.3. Competitive scenario
9.3.1.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
9.3.2. Saudi Arabia
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/ reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
9.3.3. UAE
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/ reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
9.3.4. Kuwait
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework/ reimbursement structure
9.3.4.3. Competitive scenario
9.3.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
9.3.5. Qatar
9.3.5.1. Key country dynamics
9.3.5.2. Regulatory framework/ reimbursement structure
9.3.5.3. Competitive scenario
9.3.5.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
9.3.6. Rest of Middle East
9.3.6.1. Key country dynamics
9.3.6.2. Regulatory framework/ reimbursement structure
9.3.6.3. Competitive scenario
9.3.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Share Analysis, 2024
10.4. List of Key Certification Providers/Scheme Owners
10.5. Company Profiles/Listing
10.5.1. F. Hoffmann-La Roche AG
10.5.1.1. Company overview
10.5.1.2. Financial performance
10.5.1.3. Product benchmarking
10.5.1.4. Strategic initiatives
10.5.2. Abbott
10.5.2.1. Company overview
10.5.2.2. Financial performance
10.5.2.3. Product benchmarking
10.5.2.4. Strategic initiatives
10.5.3. Thermo Fisher Scientific Inc
10.5.3.1. Company overview
10.5.3.2. Financial performance
10.5.3.3. Product benchmarking
10.5.3.4. Strategic initiatives
10.5.4. Eurofins Scientific
10.5.4.1. Company overview
10.5.4.2. Financial performance
10.5.4.3. Product benchmarking
10.5.4.4. Strategic initiatives
10.5.5. QIAGEN
10.5.5.1. Company overview
10.5.5.2. Financial performance
10.5.5.3. Product benchmarking
10.5.5.4. Strategic initiatives
10.5.6. Bio-Rad Laboratories, Inc.
10.5.6.1. Company overview
10.5.6.2. Financial performance
10.5.6.3. Product benchmarking
10.5.6.4. Strategic initiatives
10.5.7. Siemens Healthineers AG
10.5.7.1. Company overview
10.5.7.2. Financial performance
10.5.7.3. Product benchmarking
10.5.7.4. Strategic initiatives
10.5.8. Merck KGaA
10.5.8.1. Company overview
10.5.8.2. Financial performance
10.5.8.3. Product benchmarking
10.5.8.4. Strategic initiatives
10.5.9. PerkinElmer Inc.
10.5.9.1. Company overview
10.5.9.2. Financial performance
10.5.9.3. Product benchmarking
10.5.9.4. Strategic initiatives
10.5.10. Agilent Technologies, Inc.
10.5.10.1. Company overview
10.5.10.2. Financial performance
10.5.10.3. Product benchmarking
10.5.10.4. Strategic initiatives